Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | MM: The battle for new drugs

Jonathan Keats • 13 Sep 2019
IMW 2019
Multiple Myeloma

Jonathan Keats, PhD, Translational Genomics Research Institute, Phoenix, AZ, explains how the multiple myeloma (MM) drugs currently available are acting as a limiting factor in treatment progression at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Jonathan Keats

2:49
An insight into the MMRF-CoMMpass study
Jonathan Keats • 26 Mar 2022
3:58
Sample processing and enrichment techniques in myeloma research
Jonathan Keats • 2 Sep 2021
1:51
A molecular-based approach to MM treatment
Jonathan Keats • 15 Sep 2019
1:00
Proof of principle to progress treatments
Jonathan Keats • 13 Sep 2019

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals